Search results for "PROGESTERONE"

showing 10 items of 188 documents

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct

Immunoglobulin Kappa C Has Independent Prognostic Significance in Node-Negative Breast Cancer.

2009

Abstract Background: Utilizing microarray based gene-expression analysis of fresh-frozen tissue we could recently demonstrate the prognostic impact of a B cell metagene in node-negative breast cancer (Cancer Res 68: 5405-5413, 2008). In the present study we investigated the prognostic significance of immunoglobulin kappa c (IGKC) in formalin-fixed paraffin embedded (FFPE) breast cancer specimens of 363 node-negative breast cancer patients which were not treated in the adjuvant setting.Methods: RT-PCR was used to analyze mRNA expression of IGKC in FFPE tissue of 363 patients with node-negative breast cancer. Additionally to IGKC we examined the prognostic impact of age, histological grade, t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyMicroarraybusiness.industrymedicine.medical_treatmentEstrogen receptorCancermedicine.diseaseBreast cancermedicine.anatomical_structureOncologyInternal medicineProgesterone receptormedicinebusinessAdjuvantB cellCancer Research
researchProduct

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation …

2012

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin-fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. …

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryCancerRetrospective cohort studyArticlesProgesterone Receptor StatusSettore MED/08 - Anatomia Patologicamedicine.diseaseClinical trialBreast carcinoma immunohistochemistry HER2medicine.anatomical_structureOncologyTrastuzumabInternal medicineCohortsmall size breast cancer screening campaign staging immunohistochemistrymedicineBreast carcinomabusinessLymph nodemedicine.drug
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients

2003

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. χ2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor sta…

OncologyMultivariate statisticsUnivariate analysismedicine.medical_specialtyMultivariate analysisbusiness.industryProportional hazards modelObstetrics and GynecologyProgesterone Receptor Statusmedicine.diseaseOncologyInternal medicineCarcinomamedicineStage (cooking)businessSurvival analysisInternational Journal of Gynecologic Cancer
researchProduct

Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

2012

Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzedthe association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative breast cancer patients.Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological g…

OncologyPathologyB CellsEpidemiology610 MedizinEstrogen receptorlcsh:MedicineMetastasis610 Medical sciencesBasic Cancer ResearchPathologyStage (cooking)lcsh:ScienceUnivariate analysisMultidisciplinaryHazard ratioObstetrics and GynecologyMiddle AgedImmunohistochemistryOncologyMedicineFemaleResearch Articlemedicine.medical_specialtyImmune CellsImmunoglobulinsBreast NeoplasmsDisease-Free SurvivalImmunoglobulin kappa-ChainsBreast cancerDiagnostic MedicineInternal medicineProgesterone receptorBreast CancermedicineHumansAntibody-Producing CellsSurvival analysisImmune Evasionbusiness.industrylcsh:RImmunitymedicine.diseaseConfidence intervalBiomarker EpidemiologyHumoral Immunitylcsh:QClinical ImmunologybusinessBiomarkersGeneral Pathology
researchProduct

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients

2012

Diverse polymorphisms have been associated with the predisposition to develop cancer. On fewer occasions, they have been related to the evolution of the disease and to different responses to treatment. Previous studies of our group have associated polymorphisms on genes related to oxidative stress (rs3736729 on GCLC and rs207454 on XDH) and DNA damage repair (rs1052133 on OGG1) with a predisposition to develop breast cancer. In the present work, we have evaluated the hypothesis that these polymorphisms also play a role in a patient’s survival. A population-based cohort study of 470 women diagnosed with primary breast cancer and a median follow up of 52.44 months was conducted to e…

OncologyPathologyDNA Repairlcsh:ChemistryGenotypeMedicineProgesterone Receptor Negativegenetic variants; GCLC; XDH; OGG1; breast cancer; survivalOGG1lcsh:QH301-705.5SpectroscopyAged 80 and overeducation.field_of_studyGeneral MedicineMiddle AgedNeoplasm ProteinsComputer Science ApplicationsGCLCSurvival RateGCLCFemaleAdultmedicine.medical_specialtyPopulationBreast NeoplasmssurvivalArticleDisease-Free SurvivalCatalysisInorganic ChemistryBreast cancerbreast cancerMedian follow-upInternal medicineXDHHumansPhysical and Theoretical ChemistryeducationMolecular BiologyAgedPolymorphism GeneticProportional hazards modelbusiness.industrygenetic variantsOrganic ChemistryCancermedicine.diseaseOxidative Stresslcsh:Biology (General)lcsh:QD1-999businessDNA DamageFollow-Up StudiesInternational Journal of Molecular Sciences
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologis…

2013

Abstract Objectives The aim of this study is to evaluate the activity and toxicity of fulvestrant, a pure estrogen receptor antagonist in patients with advanced or recurrent endometrial cancer, expressing estrogen and/or progesterone receptors (ER/PR). Methods Eligible patients with advanced or recurrent endometrial cancer not amenable to curative surgery and/or radiotherapy were treated with fulvestrant at a dose of 250mg by IM injection every 4weeks for at least 12weeks. Therapy was continued until disease progression, death, intolerable side effects or end of study. Response was assessed in patients with at least one target lesion according to WHO-criteria. Results Thirty-five patients w…

Oncologymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentPopulationEstrogen receptorPhases of clinical researchInjections IntramuscularLoading doseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanseducationFulvestrantAgedNeoplasm Staging030304 developmental biologyAged 80 and over0303 health scienceseducation.field_of_studyEstradiolFulvestrantbusiness.industryEndometrial cancerEstrogen AntagonistsObstetrics and GynecologyMiddle Agedmedicine.diseaseEndometrial Neoplasms3. Good healthSurgeryRadiation therapyReceptors EstrogenOncologyTolerability030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalReceptors Progesteronebusinessmedicine.drugGynecologic Oncology
researchProduct

Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features …

2009

A new classification based on gene expression profiling or immunohistochemical (IHC) characteristics may replace current histopathological classifications and predict better clinical outcomes. We used IHC markers to classify incident cases ascertained by the Palermo Breast Cancer Registry (2002-2004) into four subtypes: luminal-A (ER+ or PgR+ and HER2/neu-); luminal-B (ER+ or PgR+, HER2/neu+); basal-like (ER-, PgR-, HER2/neu-); and HER2+/ER- (HER2/neu+, ER-, PgR-). We evaluated HER2/neu, ER and PgR in 1300/1985 (65%) cases. The most common IHC-subtype was luminal-A (68%), whereas luminal-B, basal-like, and HER2+/ER- accounted for 14%, 13%, and 5%, respectively. IHC-subtypes were not associa…

Oncologymedicine.medical_specialtyBreast NeoplasmsPopulation basedGeneral Biochemistry Genetics and Molecular BiologyBreast tumorBreast cancerHistory and Philosophy of ScienceInternal medicinemedicineHumansRegistriesskin and connective tissue diseasesGrading (tumors)DemographyGynecologyTumor sizebusiness.industryGeneral NeuroscienceGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistryCancer registryMenopauseItalyReceptors EstrogenPopulation SurveillanceImmunohistochemistryFemalebusinessReceptors ProgesteroneAnnals of the New York Academy of Sciences
researchProduct